Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Hematology
•
Internal Medicine
Would you use methotrexate to treat a small T-LGL clone (<650 cells/m3), with mild pancytopenia, and associated autoimmune disease such as systemic sclerosis?
Would a better alternative be consideration of a clinical trial with ruxolitinib?
Related Questions
For patients with newly diagnosed VTE on IV heparin planned for transition to DOAC, would you start at the loading or maintenance DOAC dose?
Given the data from SWOG 1826 suggesting that Nivo-AVD is likely the preferred regimen for advanced Hodgkin lymphoma patients, are there scenarios where alternative regimens may still be preferred?
How would you manage a healthy young adult patient with nodular lymphocyte predominant Hodgkin lymphoma with steroid-responsive severe hemolytic anemia and no other symptoms?
If a bone marrow biopsy reveals mast cell leukemia, would you consider treating with avapritinib?
How do you approach severe anemia and thrombocytopenia in an elderly patient whose bone marrow biopsy shows hypercellular marrow with mild dysplasia in erythroid and megakaryocytic lineage but normal cytogenetics and a negative NGS panel?
Would you consider the use of ruxolitinib for tumor fevers and leukocytosis?
If using the triplet AMPLIFY regimen with ven/acala/obin upfront, what do you then plan to use in 2nd line treatment of CLL?
In a patient with history of recurrent VTE despite anticoagulation, would you consider lenalidomide as part of your initial myeloma regimen?
How do you manage high-risk MDS IB2 patients on HMA and venetoclax who develop an acute stroke requiring antiplatelet therapy?
Is enteric-coated aspirin acceptable to use in polycythemia vera or ET?